Other Events ·
Moleculin Biotech completes enrollment of 89 subjects in pivotal Phase 2/3 MIRACLE trial for relapsed AML
MBRXMoleculin Biotech, Inc.
Moleculin Biotech announced on September 29, 2026, the completion of enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin combined with cytarabine for relapsed or refractory acute myeloid leukemia. The company enrolled 89 subjects and remains on track for a comprehensive data readout in the first quarter of 2027. Moleculin is a clinical-stage pharmaceutical company developing therapeutic candidates for hard-to-treat tumors.